Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (Q34257664)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Barbara Burtness

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Mark Powell

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Paul Catalano

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jordan Berlin

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Darla K Liles

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Andrew E Chapman

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Edith Mitchell

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Al B Benson

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

28 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

American Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

340-345

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Pancreatic cancer and thromboembolic disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Effect of CPT-11 in combination with other anticancer agents in lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

6 July 2018

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

28 October 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177955

28 October 2018

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24685886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/COC.0000000000000068

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34257664&oldid=1646329581"